Lung Cancer Trial, By Invitation NCT07401498 Sponsor: Regional Clinical Oncology Dispensary Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, By Invitation

NCT07401498
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older.
  • People who have been diagnosed with a specific stage of non-small cell lung cancer (a common type of lung cancer), ranging from early to locally advanced stages, and for whom a planned surgery aims to remove the affected part of the lung (such as a segment, lobe, or the entire lung).
  • People whose surgery will include a thorough removal and examination of nearby lymph nodes, specifically including a particular group located near the centre of the chest (confirm with trial site).
  • People who have signed a consent form agreeing to take part in the study.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have small cell lung cancer (a different type of lung cancer), non-cancerous tumours, or cancer that has spread from another part of the body to the lung.
  • People whose planned surgery involves only a small, limited removal of lung tissue without any removal of lymph nodes.
  • People whose surgery is not being done as an emergency procedure (note: if a planned surgery needs to be converted to a different surgical approach during the operation, this is acceptable) (confirm with trial site).
  • People who are unlikely to be available for follow-up contact over the 30 days after surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
Regional Clinical Oncology Dispensary
Registry
ClinicalTrials.gov
Start date
14 August 2025
Est. completion
1 August 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Frequency and outcome after Lymphadenectomy complications within 30 days after surgery

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov